Clofoctol

Clofoctol

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Rectal (suppository)
ATC code	J01XX03 (WHO)
Pharmacokinetic data
Bioavailability	98%
Metabolism	Hepatic glucuronidation
Excretion	Biliary
Identifiers
IUPAC name 2-[(2,4-dichlorophenyl)methyl]- 4-(2,4,4-trimethylpentan-2-yl)phenol
CAS Number	37693-01-9 Y
PubChem CID	2799
DrugBank	DB13237 Y
ChemSpider	2697 Y
UNII	704083NI0R
KEGG	D07244 Y
ChEMBL	ChEMBL1476605
CompTox Dashboard (EPA)	DTXSID5045889
ECHA InfoCard	100.048.739
Chemical and physical data
Formula	C21H26Cl2O
Molar mass	365.34 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1cc(Cl)ccc1Cc2cc(ccc2O)C(C)(C)CC(C)(C)C
InChI InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3 Y Key:HQVZOORKDNCGCK-UHFFFAOYSA-N Y
(verify)

Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.^{[citation needed]}

It is only functional against Gram-positive bacteria.

It penetrates into human lung tissue.

A French company, Apteeus had been developing clofoctol as a potential therapy against SARS-CoV-2 in 2020-2021, but eventually the repurposing of the drug was abandoned, due to a lack of volunteers. A mouse study showed repurposed drug clofoctol blocks SARS-CoV-2 replication.